Published in Vaccines (Basel) on July 02, 2014
A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice. PLoS One (2016) 1.40
A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines. Int J Mol Sci (2016) 0.78
Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine. PLoS One (2016) 0.77
Preparation, characterization and immunological evaluation: canine parvovirus synthetic peptide loaded PLGA nanoparticles. J Biomed Sci (2015) 0.76
MEPPitope: spatial, electrostatic and secondary structure perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus. F1000Res (2016) 0.75
Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus. Microb Cell Fact (2016) 0.75
Immunological properties of gold nanoparticles. Chem Sci (2016) 0.75
Enhancing vaccine effectiveness with delivery technology. Curr Opin Biotechnol (2016) 0.75
In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A. PLoS One (2016) 0.75
Structure-based Epitope Mapping of Mycobacterium tuberculosis Secretary Antigen MTC28. J Biol Chem (2016) 0.75
Clinical applications of mouse models for breast cancer engaging HER2/neu. Integr Cancer Sci Ther (2016) 0.75
Design of cocktail peptide vaccine against Cytomegalovirus infection. Iran J Basic Med Sci (2016) 0.75
Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates. Immun Inflamm Dis (2016) 0.75
Staphylococcal Enterotoxin B (SEB) Induces Memory CD4 T Cell Anergy in vivo and Impairs Recall Immunity to Unrelated Antigens. J Clin Cell Immunol (2015) 0.75
Solid-in-oil nanodispersions for transdermal drug delivery systems. Biotechnol J (2016) 0.75
Short peptide epitope design from hantaviruses causing HFRS. Bioinformation (2017) 0.75
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 7.86
Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol (1989) 4.29
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15
Vaccine adjuvants: current state and future trends. Immunol Cell Biol (2004) 2.74
More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov (2007) 2.68
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67
Key roles of adjuvants in modern vaccines. Nat Med (2013) 2.62
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med (1990) 2.58
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine (2011) 2.53
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol (2009) 2.49
Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol (2008) 2.30
The IMGT/HLA database. Nucleic Acids Res (2008) 2.22
T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med (1995) 2.07
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
The human antibody response to dengue virus infection. Viruses (2011) 1.79
Vaccine adjuvants revisited. Vaccine (2007) 1.69
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67
Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs (2007) 1.58
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Malaria vaccines: are we getting closer? Curr Opin Mol Ther (2007) 1.55
Recognition of influenza A virus nucleoprotein by an H-2-restricted cytotoxic T-cell clone. Virology (1984) 1.48
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol (2007) 1.35
In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes. J Immunol (1996) 1.33
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer (2006) 1.29
Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol (2004) 1.29
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother (2006) 1.23
MimoDB 2.0: a mimotope database and beyond. Nucleic Acids Res (2011) 1.18
SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol (2007) 1.18
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res (2011) 1.18
First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs. J Virol (1994) 1.17
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer (2010) 1.15
Specificity of cytotoxic T lymphocytes stimulated with influenza virus. Studies in mice and humans. Prog Allergy (1985) 1.15
Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines (2007) 1.14
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine (2012) 1.13
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother (2009) 1.13
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release (2013) 1.08
Stereocomplex block copolymer micelles: core-shell nanostructures with enhanced stability. Nano Lett (2005) 1.08
ISCOMs and ISCOMATRIX. Vaccine (2009) 1.06
Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol (2011) 1.05
Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer (2006) 1.05
Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release (2012) 1.05
Mechanisms of action of adjuvants. Front Immunol (2013) 1.05
ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol (2012) 1.03
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol (2011) 1.02
Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv (2006) 1.01
Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol (2013) 1.01
Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine (2009) 1.01
pH-triggered microparticles for peptide vaccination. J Immunol (2004) 1.00
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res (2011) 0.99
Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target (2009) 0.97
Determination of protein-derived epitopes by mass spectrometry. Expert Rev Proteomics (2005) 0.97
Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines (2010) 0.96
Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol (2002) 0.96
A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. J Immunol (2010) 0.96
Modeling of the TCR-MHC-peptide complex. J Mol Biol (2000) 0.95
Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine (2007) 0.94
In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials (2010) 0.93
Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J Hepatol (2008) 0.93
The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr Drug Targets (2002) 0.92
Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis. Mol Pharm (2012) 0.92
Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites. Peptides (2007) 0.92
Prediction of B-cell epitopes using evolutionary information and propensity scales. BMC Bioinformatics (2013) 0.91
Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol (2004) 0.89
Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. Virology (2007) 0.89
Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol (2011) 0.88
Vaccine delivery carriers: insights and future perspectives. Int J Pharm (2012) 0.88
Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol (2011) 0.87
Liposomal vaccine delivery systems. Expert Opin Drug Deliv (2011) 0.87
Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques. J Immunol (2008) 0.87
Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. Vaccine (2007) 0.86
Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine (1999) 0.86
Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomedicine (2011) 0.86
Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem (1998) 0.86
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med (2006) 0.84
Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials (2013) 0.84
Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol (2012) 0.84
Chitosan formulations improve the immunogenicity of a GnRH-I peptide-based vaccine. Int J Pharm (2008) 0.83
Study on the immunogenicity of human class-II-restricted T-cell epitopes: processing constraints, degenerate binding, and promiscuous recognition. Cold Spring Harb Symp Quant Biol (1989) 0.83
Highly efficient antiviral CD8+ T-cell induction by peptides coupled to the surfaces of liposomes. Clin Vaccine Immunol (2009) 0.82
Size-dependent impairment of cognition in mice caused by the injection of gold nanoparticles. Nanotechnology (2010) 0.82
Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Sci (2010) 0.82
Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs. Vaccine (2011) 0.82
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol (2011) 0.81
Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. Antiviral Res (2009) 0.81
Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help. Immunology (1996) 0.81
Efficient orthogonal bioconjugation of dendrimers for synthesis of bioactive nanoparticles. Bioconjug Chem (2011) 0.80
Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol Pharm (2011) 0.80
Synthetic peptide vaccines. J Med Microbiol (1993) 0.79
CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J Immunol (1996) 0.79
Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity. J Immune Based Ther Vaccines (2003) 0.78
Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine (2001) 0.78
Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses. Vaccine (1999) 0.78
Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS One (2010) 0.78
Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int J Pharm (2006) 0.78